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Abstract
Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a relatively rare clinical entity;
even more so in response to vancomycin.
Methods: Case report.
Results: We present a severe case of vancomycin-induced DRESS syndrome, which on presentation included only
skin, hematological and mild liver involvement. The patient further developed severe acute interstitial nephritis,
eosinophilic pneumonitis, central nervous system (CNS) involvement and worsening hematological abnormalities
despite immediate discontinuation of vancomycin and parenteral corticosteroids. High-dose corticosteroids for a
prolonged period were necessary and tapering of steroids a challenge due to rebound-eosinophilia and skin
involvement.
Conclusion: Patients with DRESS who are relatively resistant to corticosteroids with delayed onset of certain organ
involvement should be treated with a more prolonged corticosteroid tapering schedule. Vancomycin is increasingly
being recognized as a culprit agent in this syndrome.
Introduction
We present a case of severe Drug Reaction with Eosino-
philia and Systemic Symptoms (DRESS) [1] syndrome
secondary to vancomycin, with associated multiorgan
dysfunction. The relatively high mortality of this syn-
drome warrants prompt recognition and elimination of
the culprit drug and often treatment with high-dose
corticosteroids.
Case Report
A 66 year-old male presented to the emergency depart-
ment (ED) with a one-week history of progressive pruri-
tic erythematous rash, dry cough and two days of
episodic high fevers. He had suffered a fall 12 weeks
prior that had resulted in a pelvic fracture requiring an
open-reduction internal fixation, which subsequently
became infected with methicillin-resistant Staphylococ-
cus aureus (MRSA) and treatment with intravenous
vancomycin was initiated. After four weeks of vancomy-
cin therapy he developed a rash. This was initially
thought to be due to a red-man syndrome variant. Infu-
sion rates were slowed, and premedication with diphen-
hydramine was initiated, but the rash worsened, with
the subsequent development of episodic daily fevers,
documented to be as high as 40°C.
His past medical history was significant for heterozy-
gous hemochromatosis, a remote splenectomy secondary
to traumatic rupture, and non-anaphylactic adverse
reactions to penicillin and sulfa antibiotics. He had no
history of reactive airway disease and had no travel his-
tory, living in an Ontario city.
In the ED he was hemodynamically stable with a nor-
mal mental status. He had a severe erythematous macu-
lar rash involving his face and trunk (see Figure 1), and
some facial edema. He had no mucous membrane invol-
vement. He had palpable bilateral cervical and left axil-
lary lymphadenopathy. Cardiorespiratory examination
was normal, and his abdominal exam revealed central
obesity and a scar from his remote splenectomy. Initial
laboratory investigations are shown in Table 1. A
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computed tomography (CT) scan of his pelvis showed
no abscess formation. A skin biopsy of the initial rash
showed a mild perivascular lymphocytic infiltrate, con-
sistent with a drug reaction.
Our initial working diagnosis was Drug Reaction with
Eosinophilia and Systemic Symptoms (DRESS) second-
ary to vancomycin, which was immediately discontinued.
Initially, his liver enzymes and eosinophilia appeared to
improve spontaneously, thus management was mainly
supportive with topical hydrocortisone and oral H1 and
H2 receptor antagonists (cetirizine 20 mg PO BID and
ranitidine 150 mg PO BID). On the third day of admis-
sion, however, his white blood cell (WBC) and eosino-
phil counts increased and continued to rise (see Figure
2) leading to the initiation of systemic corticosteroids.
He was initially given hydrocortisone 40 mg IV every 8
hours for 2 days followed by prednisone 60 mg PO
daily. Despite this treatment, his eosinophil count con-
tinued to rise and peaked on Day 10 (see Figure 2). He
became dyspneic with diffuse wheezing on exam, requir-
ing repeated bronchodilator treatments. The chest x-ray
was repeated and a CT chest performed. Chest imaging
revealed a diffuse interstitial pattern that was suggestive
of eosinophilic pneumonitis (Figure 3). There was no
evidence clinically or on echocardiography of heart fail-
ure. While initially his renal function was close to nor-
mal, starting on Day 8 it began to worsen (see Figure 2),
peaking on Day 18 at 432 micromol/L despite aggressive
fluid administration and good urine output. A renal
ultrasound was normal, but microscopic urinalysis
revealed persistent WBC casts consistent with worsening
interstitial nephritis as an explanation for the acute renal
Figure 1 Patient’s rash on presentation.
Table 1 Laboratory Investigations (Initial)
Parameter Value Reference (Units) Parameter Value Reference (Units)
Creatinine 120 50-100 umol/L WBC 30.2 4.0-10.5 x10^9/L
Urea 6.5 3.0-6.5 umol/L Eosinophils 3.62 0.0-0.4 x10^9/L
Sodium 126 135-145 mmol/L Neutrophils 19.34 2.00-7.50 x10^9/L
Potassium 3.8 3.5-5.0 mmol/L Lymphocytes 2.11 1.5-4.00 x10^9/L
Chloride 93 98-107 mmol/L Hb 114 140-170 g/L
Glucose 5.0 3.5-11.1 mmol/L Platelets 604 150-400 x10^9/L
Total Protein 49 60-80 g/L ESR 20 < 30 mm/hr
Albumin 21 35-50 g/L CRP 13.4 < 3.0 mg/L
INR 1.3 0.9-1.2 C3 1.22 0.80-1.8 g/L
Bilirubin 14 0-17 umol/L C4 0.27 0.13-0.40 g/L
GGT 354 8-61 U/L IgA 3.04 0.80-4.50 g/L
Alk Phos 708 56-119 U/L IgD < 140 mg/L
AST 163 12-45 U/L IgE 70 < 129 IU/mL
ALT 144 7-40 U/L IgG 13.02 6.00-16.00 g/L
CK 17 55-197 U/L IgM 0.33 0.40-3.00 g/L
LDH 196 94-250 U/L
Lactate 3.1 0.5-2.2 mmol/L c-ANCA Negative
Blood cultures Negative p-ANCA Negative
Hepatitis B&C Negative ANA Negative
EBV serology past exposure ENA Negative
Stool O&P Negative SPEP Negative
Strongyloidiasis serology Negative UPEP Negative
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failure. During this time, he became delirious, with no
causative abnormalities found on neurological examina-
tion, laboratory investigations or CT head, indicating
the likely cause to be his underlying DRESS. High dose
methylprednisolone 125 mg IV q8 hourly was initiated,
and his renal function slowly improved, negating the
need for a renal biopsy in the opinion of the consultant
nephrologist. His wheezing and mental status also
improved with the subsequent reduction in his WBC
and eosinophil counts. Peripheral blood flow cytometry
did reveal an atypical plasmacytoid population, but
serum and urinary protein electrophoresis were negative
for a monoclonal protein.
Our initially broad differential diagnosis was narrowed
as our patient’s clinical presentation developed. Red
man syndrome, an infusion and dose-related mast cell
degranulation in reaction to impurities found in vanco-
mycin, was excluded early upon hospital presentation
[2]. The fact that his rash persisted despite vancomycin
discontinuation, the multisystem nature of his presenta-
tion and the moderate eosinophilia was suspicious for a
more serious process. Churg-Strauss Syndrome (CSS)
Figure 2 Graph illustrating the eosinophil and creatinine trend over the course of the first three months following presentation.
Figure 3 Chest X-ray showing an interstitial pattern suggestive
of eosinophilic pneumonitis in this patient.
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was also considered, but our patient had no history of
asthma or any bronchodilator or corticosteroid use in
the past, and therefore it was lower on our differential.
Nonetheless, anti-neutrophil cytoplasmic antibodies
(ANCAs), a test with only about 40% sensitivity for CSS,
was sent and found to be negative [3]. This was sent 8
days after initiation of corticosteroids, which may have
decreased the test’s sensitivity. However the predictive
value of a negative ANCA in the face of our low clinical
probability was sufficient to exclude this diagnosis. CSS,
often described as having three phases, the asthmatic,
the hypereosinophilic and the vasculitic phases, is
almost always preceded by a usually escalating asthmatic
phase that can last up to years and is rarely subtle [3].
Seldom, asthma can be a late feature. However, we have
followed our patient over time, and complete tapering
of corticosteroid left him with no residual respiratory
symptoms, making CSS highly unlikely.
Microscopic stool examination for ova and parasites
was negative as was Stongyloides stercoralis serology. No
further parasitic work-up was completed as the patient
had no risk factors or gastrointestinal symptoms. Severe
systemic bacterial infections, with the exception of scar-
let fever, cause eosinopenia [4], and at the time of
admission our patient had in fact been recovering from
an MRSA bacteremia. Genetic testing for hypereosino-
philic syndromes (HESs) with FIP1L1 and PDGFRA
were negative, and although these are positive in only
about 30% of patients with HESs [5], a secondary cause
of hypereosinophilia was apparent and thus helped
exclude this diagnosis with more certainty.
On day 39 from initial presentation, our patient
returned to hospital with a methicillin-sensitive Staphy-
lococcus aureus (MSSA) bacteremia and severe left
shoulder pain. He was admitted under orthopedic sur-
gery for exploration and debridement of both the
shoulder and pelvis as well as removal of the pelvic
hardware. Evidence of osteomyelitis in the pelvic bone
was found during the surgery. He remains on cefazolin
and is being followed by the infectious diseases service.
Meanwhile, a taper of his prednisone was attempted
around day 50 over a two week period. Unfortunately,
his rash and eosinophilia returned shortly after its dis-
continuation, requiring re-initiation and a slower taper-
ing attempt. This was finally successful more than four
months after initial presentation. He is currently mana-
ged with an oral H1 receptor antagonist alone, and his
peripheral eosinophil count has remained suppressed.
Discussion
Drug Reaction with Eosinophilia and Systemic Symp-
toms (DRESS) is an idiosyncratic hypersensitivity
response characterized by a maculopapular erythema-
tous eruption that typically develops 2-6 weeks following
initiation of the culprit drug. The typical findings
include fever, lymphadenopathy, multisystem organ fail-
ure and eosinophilia or atypical lymphocytosis. The
term DRESS was coined in 1996 by Bocquet et al., in an
attempt to unify the many names given to different drug
reactions thought to have a common pathophysiological
mechanism [6]. It has been postulated that concomitant
infection with herpes-simplex virus-6 (HSV-6) predis-
poses to development of DRESS [7] and recently sug-
gested as a diagnostic requirement [8]. Multi-organ
failure often presents in a stepwise fashion despite dis-
continuation of the culprit drug. The affected organs
include, in order of frequency, the skin, liver, kidneys,
lungs, heart, and more rarely CNS, thyroid, pancreas,
colon, muscles and serosa. The most common drugs
that cause DRESS are anti-epileptics, the first described
being phenytoin in 1939 [9]. Nine cases of vancomycin-
induced DRESS syndrome have been described so far in
the English literature [10-18]. As well, a tenth case,
although not labeled as such, fulfills the criteria of
DRESS [19]. None of the described cases appear to have
been as severe as what was observed in our case, and
our patient was initially refractory to corticosteroids
with a late onset to his acute kidney injury from intersti-
tial nephritis.
Identifying patients with this syndrome is important,
as mortality approaches 10% [1]. Treatment includes
strict discontinuation of the culprit drug(s). Also, prob-
ability tools exist to help identify the most likely agents
[20]. Supportive care with symptomatic treatment using
H1 and H2 receptor antagonists and topical steroid
treatment may be sufficient for some. It is recom-
mended to start systemic corticosteroids when internal
organ involvement is present [21]. Despite the lack of
randomized controlled trials comparing supportive care
alone to systemic steroids in the treatment of DRESS,
experience has dictated their use and they are recom-
mended by experts [15]. The use of systemic corticoster-
oids is further supported by observations of clinical
worsening with early tapering of the same [22]. Occa-
sionally, additional immunosuppressive therapy is neces-
sary and has been observed to improve organ function
[8].
Conclusion
We present a case of a patient with a relatively severe
DRESS syndrome secondary to vancomycin with multi-
ple organ systems affected, including skin, hematologi-
cal, liver, lung, brain and kidneys in a stepwise fashion.
Onset of renal injury from acute interstitial nephritis
was delayed and the response to standard doses of par-
enteral corticosteroids insufficient despite initial sponta-
neous improvements with the discontinuation of the
offending drug. Additionally, skin and hematological
O’Meara et al. Allergy, Asthma & Clinical Immunology 2011, 7:16
http://www.aacijournal.com/content/7/1/16
Page 4 of 5
abnormalities recurred once corticosteroids were
tapered. Patients with DRESS who are relatively resistant
to corticosteroids with delayed onset of certain organ
involvement should be treated with a more prolonged
corticosteroid tapering schedule. Vancomycin is increas-
ingly being recognized as a culprit agent in this
syndrome.
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